Lupin receives approval from U.S. FDA for Sildenafil for Oral Suspension

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL to market a generic equivalent of Revatio® for Oral Suspension, 10 mg/mL, of Viatris Specialty LLC. The product will be manufactured at Lupin's facility in Goa, India.

Sildenafil for Oral Suspension, 10 mg/mL (RLD Revatio®) had estimated annual sales of USD 66 million in the U.S. (IQVIA MAT December 2021).

Shares of Lupin Limited was last trading in BSE at Rs. 747.10 as compared to the previous close of Rs. 756.65. The total number of shares traded during the day was 32863 in over 1580 trades.

The stock hit an intraday high of Rs. 770.00 and intraday low of 744.00. The net turnover during the day was Rs. 24866248.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA ANDA Approval Sildenafil OralSuspension Revatio ViatrisSpecialtyLLC